Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.

Acta pharmacologica Sinica - 1 Feb 2019

Li Qing-Rou, Zhao Hui, Zhang Xue-Sai, Lang Henk, Yu Ker

Abstract excerpt

The G protein-coupled receptor (GPCR) smoothened (SMO) is a key signaling component of the sonic hedgehog (Hh) pathway and a clinically validated target for cancer treatment. The FDA-approved SMO inhibitors GDC-0449/Vismodegib and LDE225/Sonidegib demonstrated clinical antitumor efficacy. Nevertheless, relatively high percentage of treated patients would eventually develop acquired cross resistance to both drugs....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Benzimidazoles

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Down-Regulation

Share to HEK293 Cells

Share to Mice, Inbred BALB C

Share to NIH 3T3 Cells

Share to Smoothened Receptor

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 29777201
DOI: 10.1038/s41401-018-0019-5
PMCID: PMC6329794

Genes

SMO
SHH

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel-smoothened inhibitors for therapeutic targeting of naïve and drug-resistant hedgehog pathway-driven cancers.PMID 29777201Read ↗

Next-Generation Hedgehog/GLI Pathway Inhibitors for Cancer TherapySemantic proximity Read ↗

Hedgehog pathway inhibitors: a patent review (2009 – present)Semantic proximity Read ↗

Casein kinase 1D encodes a novel drug target in Hedgehog-GLI driven cancers and tumor-initiating cells resistant to SMO inhibitionSemantic proximity Read ↗

Hedgehog pathway as a drug target: Smoothened inhibitors in developmentSemantic proximity Read ↗

The Utility of Hedgehog Signaling Pathway Inhibition for CancerSemantic proximity Read ↗

Design of Hedgehog pathway inhibitors for cancer treatmentSemantic proximity Read ↗

The SHH/GLI signaling pathway: a therapeutic target for medulloblastomaSemantic proximity Read ↗

Beyond cyclopamine: Targeting Hedgehog signaling for cancer interventionSemantic proximity Read ↗

Small-molecule inhibitors reveal multiple strategies for Hedgehog pathway blockade.Semantic proximity Read ↗

Molecular Pathways: Novel Approaches for Improved Therapeutic Targeting of Hedgehog Signaling in Cancer Stem CellsSemantic proximity Read ↗

Unraveling the therapeutic potential of the Hedgehog pathway in cancer.Semantic proximity Read ↗

Small molecule inhibition of GDC-0449 refractory smoothened mutants and downstream mechanisms of drug resistance.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.